{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:59:15Z","timestamp":1789822755511,"version":"4.0.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T00:00:00Z","timestamp":1498089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s11914-017-0380-1","type":"journal-article","created":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T08:45:43Z","timestamp":1498121143000},"page":"283-292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":137,"title":["Denosumab: an Emerging Therapy in Pediatric Bone Disorders"],"prefix":"10.1007","volume":"15","author":[{"given":"Alison M.","family":"Boyce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,22]]},"reference":[{"issue":"3","key":"380_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1615\/CritRevEukarGeneExpr.v19.i3.40","volume":"19","author":"E Seeman","year":"2009","unstructured":"Seeman E. Bone modeling and remodeling. Crit Rev Eukaryot Gene Expr. 2009;19(3):219\u201333.","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"Suppl 53","key":"380_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/ajpa.21612","volume":"146","author":"JH Gosman","year":"2011","unstructured":"Gosman JH, Stout SD, Larsen CS. Skeletal biology over the life span: a view from the surfaces. Am J Phys Anthropol. 2011;146(Suppl 53):86\u201398. doi: 10.1002\/ajpa.21612 .","journal-title":"Am J Phys Anthropol"},{"key":"380_CR3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000381045","volume":"28","author":"W Hogler","year":"2015","unstructured":"Hogler W, Ward L. Osteoporosis in children with chronic disease. Endocr Dev. 2015;28:176\u201395. doi: 10.1159\/000381045 .","journal-title":"Endocr Dev"},{"issue":"1","key":"380_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00223-013-9794-7","volume":"94","author":"N Kovacic","year":"2014","unstructured":"Kovacic N, Croucher PI, McDonald MM. Signaling between tumor cells and the host bone marrow microenvironment. Calcif Tissue Int. 2014;94(1):125\u201339. doi: 10.1007\/s00223-013-9794-7 .","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"380_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165\u201376.","journal-title":"Cell"},{"issue":"7","key":"380_CR6","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","volume":"96","author":"H Hsu","year":"1999","unstructured":"Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A. 1999;96(7):3540\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"380_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309\u201319.","journal-title":"Cell"},{"issue":"4","key":"380_CR8","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jama.292.4.490","volume":"292","author":"LC Hofbauer","year":"2004","unstructured":"Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases. JAMA. 2004;292(4):490\u20135. doi: 10.1001\/jama.292.4.490 .","journal-title":"JAMA"},{"issue":"12","key":"380_CR9","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2165\/11594240-000000000-00000","volume":"50","author":"L Sutjandra","year":"2011","unstructured":"Sutjandra L, Rodriguez RD, Doshi S, et al. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet. 2011;50(12):793\u2013807. doi: 10.2165\/11594240-000000000-00000 .","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"380_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2165\/11598090-000000000-00000","volume":"51","author":"L Gibiansky","year":"2012","unstructured":"Gibiansky L, Sutjandra L, Doshi S, et al. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. Clin Pharmacokinet. 2012;51(4):247\u201360. doi: 10.2165\/11598090-000000000-00000 .","journal-title":"Clin Pharmacokinet"},{"key":"380_CR11","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1038\/psp.2014.38","volume":"3","author":"S Zheng","year":"2014","unstructured":"Zheng S, Gaitonde P, Andrew MA, Gibbs MA, Lesko LJ, Schmidt S. Model-based assessment of dosing strategies in children for monoclonal antibodies exhibiting target-mediated drug disposition. CPT Pharm Systems Pharmacol. 2014;3:e138. doi: 10.1038\/psp.2014.38 .","journal-title":"CPT Pharm Systems Pharmacol"},{"issue":"8","key":"380_CR12","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"\u2022\u2022 Cummings SR, San Martin J, MR MC, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756\u201365. doi: 10.1056\/NEJMoa0809493 . The pivotal FREEDOM study was the first randomized, placebo-controlled trial of denosumab to demonstrate a decrease in vertebral and non-vertebral fractures in adults with osteoporosis.","journal-title":"N Engl J Med"},{"issue":"7","key":"380_CR13","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1210\/jc.2013-4175","volume":"99","author":"T Nakamura","year":"2014","unstructured":"Nakamura T, Matsumoto T, Sugimoto T, et al. Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab. 2014;99(7):2599\u2013607. doi: 10.1210\/jc.2013-4175 .","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"380_CR14","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1210\/jc.2007-2814","volume":"93","author":"HG Bone","year":"2008","unstructured":"Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93(6):2149\u201357. doi: 10.1210\/jc.2007-2814 .","journal-title":"J Clin Endocrinol Metab"},{"key":"380_CR15","doi-asserted-by":"publisher","unstructured":"Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res Off J Am Soc Bone Miner Res. 2009;1\u201334. doi: 10.1359\/jbmr.080910 .","DOI":"10.1359\/jbmr.080910"},{"issue":"1","key":"380_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"DL Kendler","year":"2010","unstructured":"Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res Off J Am Soc Bone Miner Res. 2010;25(1):72\u201381. doi: 10.1359\/jbmr.090716 .","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"1","key":"380_CR17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","volume":"23","author":"N Freemantle","year":"2012","unstructured":"Freemantle N, Satram-Hoang S, Tang ET, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found U S A. 2012;23(1):317\u201326. doi: 10.1007\/s00198-011-1780-1 .","journal-title":"Osteoporos Int J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found U S A"},{"issue":"12","key":"380_CR18","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","volume":"26","author":"S Papapoulos","year":"2015","unstructured":"Papapoulos S, Lippuner K, Roux C, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found U S A. 2015;26(12):2773\u201383. doi: 10.1007\/s00198-015-3234-7 .","journal-title":"Osteoporos Int J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found U S A"},{"issue":"8","key":"380_CR19","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745\u201355. doi: 10.1056\/NEJMoa0809003 .","journal-title":"N Engl J Med"},{"issue":"30","key":"380_CR20","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1200\/jco.2008.16.3832","volume":"26","author":"GK Ellis","year":"2008","unstructured":"Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(30):4875\u201382. doi: 10.1200\/jco.2008.16.3832 .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"380_CR21","unstructured":"Prolia [package insert]. Thousand Oaks, CA. 2016;Amgen, Inc."},{"issue":"35","key":"380_CR22","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/jco.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(35):5132\u20139. doi: 10.1200\/jco.2010.29.7101 .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9768","key":"380_CR23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/s0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813\u201322. doi: 10.1016\/s0140-6736(10)62344-6 .","journal-title":"Lancet"},{"issue":"9","key":"380_CR24","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/jco.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(9):1125\u201332. doi: 10.1200\/jco.2010.31.3304 .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"380_CR25","unstructured":"Xgeva [package insert]. Thousand Oaks, CA. 2016;Amgen, Inc."},{"issue":"13","key":"380_CR26","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","volume":"51","author":"JJ Body","year":"2015","unstructured":"Body JJ, Bone HG, de Boer RH, et al. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer (Oxford, England: 1990). 2015;51(13):1812\u201321. doi: 10.1016\/j.ejca.2015.05.016 .","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"9","key":"380_CR27","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1210\/jc.2014-1001","volume":"99","author":"MI Hu","year":"2014","unstructured":"Hu MI, Glezerman IG, Leboulleux S, et al. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab. 2014;99(9):3144\u201352. doi: 10.1210\/jc.2014-1001 .","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"380_CR28","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.ejca.2015.04.017","volume":"51","author":"IJ Diel","year":"2015","unstructured":"Diel IJ, Body JJ, Stopeck AT, et al. The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. Eur J Cancer (Oxford, England: 1990). 2015;51(11):1467\u201375. doi: 10.1016\/j.ejca.2015.04.017 .","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"18","key":"380_CR29","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1056\/NEJMc1206193","volume":"367","author":"R Shroff","year":"2012","unstructured":"Shroff R, Beringer O, Rao K, Hofbauer LC, Schulz A. Denosumab for post-transplantation hypercalcemia in osteopetrosis. N Engl J Med. 2012;367(18):1766\u20137. doi: 10.1056\/NEJMc1206193 .","journal-title":"N Engl J Med"},{"issue":"2","key":"380_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s13277-015-3094-y","volume":"36","author":"PF Wu","year":"2015","unstructured":"Wu PF, Tang JY, Li KH. RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects. Tumour Biol J Int Soc Oncodev Biol Med. 2015;36(2):495\u2013501. doi: 10.1007\/s13277-015-3094-y .","journal-title":"Tumour Biol J Int Soc Oncodev Biol Med"},{"issue":"5","key":"380_CR31","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1634\/theoncologist.2013-0432","volume":"19","author":"L Heijden van der","year":"2014","unstructured":"van der Heijden L, Dijkstra PD, van de Sande MA, et al. The clinical approach toward giant cell tumor of bone. Oncologist. 2014;19(5):550\u201361. doi: 10.1634\/theoncologist.2013-0432 .","journal-title":"Oncologist"},{"issue":"9","key":"380_CR32","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/s1470-2045(13)70277-8","volume":"14","author":"S Chawla","year":"2013","unstructured":"\u2022\u2022 Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013;14(9):901\u20138. doi: 10.1016\/s1470-2045(13)70277-8 . This open-label study in giant cell tumors included adults and ten skeletally mature adolescents, and demonstrated improvement in tumor progression and skeletal morbidity.","journal-title":"Lancet Oncol"},{"issue":"9","key":"380_CR33","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3109\/0284186x.2014.910313","volume":"53","author":"J Martin-Broto","year":"2014","unstructured":"Martin-Broto J, Cleeland CS, Glare PA, et al. Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study. Acta Oncol (Stockholm, Sweden). 2014;53(9):1173\u20139. doi: 10.3109\/0284186x.2014.910313 .","journal-title":"Acta Oncol (Stockholm, Sweden)"},{"issue":"12","key":"380_CR34","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1200\/jco.2012.46.4255","volume":"31","author":"NA Karras","year":"2013","unstructured":"Karras NA, Polgreen LE, Ogilvie C, Manivel JC, Skubitz KM, Lipsitz E. Denosumab treatment of metastatic giant-cell tumor of bone in a 10-year-old girl. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(12):e200\u20132. doi: 10.1200\/jco.2012.46.4255 .","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"380_CR35","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/pbc.25393","volume":"62","author":"N Gossai","year":"2015","unstructured":"Gossai N, Hilgers MV, Polgreen LE, Greengard EG. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone. Pediatr Blood Cancer. 2015;62(6):1078\u201380. doi: 10.1002\/pbc.25393 .","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"380_CR36","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s00774-015-0677-z","volume":"34","author":"N Setsu","year":"2016","unstructured":"Setsu N, Kobayashi E, Asano N, et al. Severe hypercalcemia following denosumab treatment in a juvenile patient. J Bone Miner Metab. 2016;34(1):118\u201322. doi: 10.1007\/s00774-015-0677-z .","journal-title":"J Bone Miner Metab"},{"issue":"9967","key":"380_CR37","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/s0140-6736(14)61338-6","volume":"385","author":"E Kobayashi","year":"2015","unstructured":"Kobayashi E, Setsu N. Osteosclerosis induced by denosumab. Lancet (London, England). 2015;385(9967):539. doi: 10.1016\/s0140-6736(14)61338-6 .","journal-title":"Lancet (London, England)"},{"issue":"10028","key":"380_CR38","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/s0140-6736(15)00728-x","volume":"387","author":"A Forlino","year":"2016","unstructured":"Forlino A, Marini JC. Osteogenesis imperfecta. Lancet (London, England). 2016;387(10028):1657\u201371. doi: 10.1016\/s0140-6736(15)00728-x .","journal-title":"Lancet (London, England)"},{"issue":"4","key":"380_CR39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/ajmg.c.31532","volume":"172","author":"R Marom","year":"2016","unstructured":"Marom R, Lee YC, Grafe I, Lee B. Pharmacological and biological therapeutic strategies for osteogenesis imperfecta. Am J med Genet C: Semin Med Genet. 2016;172(4):367\u201383. doi: 10.1002\/ajmg.c.31532 .","journal-title":"Am J med Genet C: Semin Med Genet"},{"issue":"1","key":"380_CR40","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1359\/jbmr.2002.17.1.30","volume":"17","author":"FH Glorieux","year":"2002","unstructured":"Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res Off J Am Soc Bone Miner Res. 2002;17(1):30\u20138. doi: 10.1359\/jbmr.2002.17.1.30 .","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"3","key":"380_CR41","first-page":"183","volume":"12","author":"O Semler","year":"2012","unstructured":"Semler O, Netzer C, Hoyer-Kuhn H, Becker J, Eysel P, Schoenau E. First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact. 2012;12(3):183\u20138.","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"380_CR42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13023-014-0145-1","volume":"9","author":"H Hoyer-Kuhn","year":"2014","unstructured":"Hoyer-Kuhn H, Netzer C, Koerber F, Schoenau E, Semler O. Two years\u2019 experience with denosumab for children with osteogenesis imperfecta type VI. Orphanet J Rare Dis. 2014;9:145. doi: 10.1186\/s13023-014-0145-1 .","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"380_CR43","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s00223-016-0110-1","volume":"98","author":"L Ward","year":"2016","unstructured":"Ward L, Bardai G, Moffatt P, et al. Osteogenesis imperfecta type VI in individuals from Northern Canada. Calcif Tissue Int. 2016;98(6):566\u201372. doi: 10.1007\/s00223-016-0110-1 .","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"380_CR44","first-page":"24","volume":"16","author":"H Hoyer-Kuhn","year":"2016","unstructured":"Hoyer-Kuhn H, Franklin J, Allo G, et al. Safety and efficacy of denosumab in children with osteogenesis imperfect\u2014a first prospective trial. J Musculoskelet Neuronal Interact. 2016;16(1):24\u201332.","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"1","key":"380_CR45","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.berh.2007.11.005","volume":"22","author":"SH Ralston","year":"2008","unstructured":"Ralston SH. Juvenile Paget\u2019s disease, familial expansile osteolysis and other genetic osteolytic disorders. Best Pract Res Clin Rheumatol. 2008;22(1):101\u201311. doi: 10.1016\/j.berh.2007.11.005 .","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"8","key":"380_CR46","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1210\/jc.2013-1143","volume":"98","author":"C Grasemann","year":"2013","unstructured":"Grasemann C, Schundeln MM, Hovel M, et al. Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget\u2019s disease. J Clin Endocrinol Metab. 2013;98(8):3121\u20136. doi: 10.1210\/jc.2013-1143 .","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"380_CR47","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1002\/jbmr.1603","volume":"27","author":"AM Boyce","year":"2012","unstructured":"Boyce AM, Chong WH, Yao J, et al. Denosumab treatment for fibrous dysplasia. J Bone Miner Res Off J Am Soc Bone Miner Res. 2012;27(7):1462\u201370. doi: 10.1002\/jbmr.1603 .","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"3","key":"380_CR48","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1210\/jc.2013-3081","volume":"99","author":"HD Wang","year":"2014","unstructured":"\u2022 Wang HD, Boyce AM, Tsai JY, et al. Effects of denosumab treatment and discontinuation on human growth plates. J Clin Endocrinol Metab. 2014;99(3):891\u20137. doi: 10.1210\/jc.2013-3081 . This study provided histopathologic evidence that denosumab treatment did not appear to adversely affect growth plates in a growing child.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"380_CR49","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1016\/j.joms.2014.06.456","volume":"72","author":"A Naidu","year":"2014","unstructured":"Naidu A, Malmquist MP, Denham CA, Schow SR. Management of central giant cell granuloma with subcutaneous denosumab therapy. J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg. 2014;72(12):2469\u201384. doi: 10.1016\/j.joms.2014.06.456 .","journal-title":"J Oral Maxillofac Surg Off J Am Assoc Oral Maxillofac Surg"},{"issue":"6","key":"380_CR50","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00586-013-2715-7","volume":"22","author":"T Lange","year":"2013","unstructured":"Lange T, Stehling C, Frohlich B, et al. Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts. Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deformity Soc Eur Sect Cervical Spine Res Soc. 2013;22(6):1417\u201322. doi: 10.1007\/s00586-013-2715-7 .","journal-title":"Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deformity Soc Eur Sect Cervical Spine Res Soc"},{"issue":"2","key":"380_CR51","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.trsl.2014.03.005","volume":"164","author":"DW Pelle","year":"2014","unstructured":"Pelle DW, Ringler JW, Peacock JD, et al. Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response. Transl Res J Lab Clin Med. 2014;164(2):139\u201348. doi: 10.1016\/j.trsl.2014.03.005 .","journal-title":"Transl Res J Lab Clin Med"},{"issue":"5 Pt 1","key":"380_CR52","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1542\/peds.111.5.1030","volume":"111","author":"L Zeitlin","year":"2003","unstructured":"Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics. 2003;111(5 Pt 1):1030\u20136.","journal-title":"Pediatrics"},{"issue":"4","key":"380_CR53","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1515\/jpem-2006-190410","volume":"19","author":"E Unal","year":"2006","unstructured":"Unal E, Abaci A, Bober E, Buyukgebiz A. Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis. J Pediatr Endocrinol Metab: JPEM. 2006;19(4):523\u20138.","journal-title":"J Pediatr Endocrinol Metab: JPEM"},{"issue":"12","key":"380_CR54","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1002\/jbmr.2567","volume":"30","author":"T Palomo","year":"2015","unstructured":"Palomo T, Fassier F, Ouellet J, et al. Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years. J Bone Miner Res Off J Am Soc Bone Miner Res. 2015;30(12):2150\u20137. doi: 10.1002\/jbmr.2567 .","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"4","key":"380_CR55","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.bone.2006.11.020","volume":"40","author":"F Rauch","year":"2007","unstructured":"Rauch F, Cornibert S, Cheung M, Glorieux FH. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone. 2007;40(4):821\u20137. doi: 10.1016\/j.bone.2006.11.020 .","journal-title":"Bone"},{"issue":"6717","key":"380_CR56","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/16852","volume":"397","author":"YY Kong","year":"1999","unstructured":"Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315\u201323. doi: 10.1038\/16852 .","journal-title":"Nature"},{"issue":"11","key":"380_CR57","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1210\/jc.2014-3072","volume":"99","author":"H Hoyer-Kuhn","year":"2014","unstructured":"Hoyer-Kuhn H, Semler O, Schoenau E. Effect of denosumab on the growing skeleton in osteogenesis imperfecta. J Clin Endocrinol Metab. 2014;99(11):3954\u20135. doi: 10.1210\/jc.2014-3072 .","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"380_CR58","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","volume":"19","author":"WX Qi","year":"2014","unstructured":"Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2014;19(2):403\u201310. doi: 10.1007\/s10147-013-0561-6 .","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"380_CR59","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res Off J Am Soc Bone Miner Res. 2015;30(1):3\u201323. doi: 10.1002\/jbmr.2405 .","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"2","key":"380_CR60","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00198-015-3355-z","volume":"27","author":"J Selga","year":"2016","unstructured":"Selga J, Nunez JH, Minguell J, Lalanza M, Garrido M. Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review. Osteoporos Int J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found U S A. 2016;27(2):827\u201332. doi: 10.1007\/s00198-015-3355-z .","journal-title":"Osteoporos Int J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found U S A"},{"issue":"2","key":"380_CR61","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1359\/jbmr.081113","volume":"24","author":"LC Gerstenfeld","year":"2009","unstructured":"Gerstenfeld LC, Sacks DJ, Pelis M, et al. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res Off J Am Soc Bone Miner Res. 2009;24(2):196\u2013208. doi: 10.1359\/jbmr.081113 .","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"4","key":"380_CR62","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972\u201380. doi: 10.1210\/jc.2010-1502 .","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"380_CR63","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1007\/s00198-016-3535-5","volume":"27","author":"AS Koldkjaer Solling","year":"2016","unstructured":"Koldkjaer Solling AS, Harslof T, Kaal A, Rejnmark L, Langdahl B. Hypercalcemia after discontinuation of long-term denosumab treatment. Osteoporos Int J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found U S A. 2016;27(7):2383\u20136. doi: 10.1007\/s00198-016-3535-5 .","journal-title":"Osteoporos Int J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found U S A"},{"issue":"9","key":"380_CR64","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1172\/jci15952","volume":"110","author":"F Rauch","year":"2002","unstructured":"Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest. 2002;110(9):1293\u20139. doi: 10.1172\/jci15952 .","journal-title":"J Clin Invest"},{"issue":"1","key":"380_CR65","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1148\/radiology.184.1.1609087","volume":"184","author":"EL van Persijn van Meerten","year":"1992","unstructured":"van Persijn van Meerten EL, Kroon HM, Papapoulos SE. Epi- and metaphyseal changes in children caused by administration of bisphosphonates. Radiology. 1992;184(1):249\u201354.","journal-title":"Radiology"},{"issue":"7","key":"380_CR66","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1359\/jbmr.040303","volume":"19","author":"F Rauch","year":"2004","unstructured":"Rauch F, Travers R, Munns C, Glorieux FH. Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res Off J Am Soc Bone Miner Res. 2004;19(7):1191\u20133. doi: 10.1359\/jbmr.040303 .","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"4","key":"380_CR67","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/jbmr.1808","volume":"28","author":"JP Brown","year":"2013","unstructured":"Brown JP, Roux C, Torring O, et al. Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res Off J Am Soc Bone Miner Res. 2013;28(4):746\u201352. doi: 10.1002\/jbmr.1808 .","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"5","key":"380_CR68","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","volume":"27","author":"B Aubry-Rozier","year":"2016","unstructured":"Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found U S A. 2016;27(5):1923\u20135. doi: 10.1007\/s00198-015-3380-y .","journal-title":"Osteoporos Int J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found U S A"},{"issue":"2","key":"380_CR69","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/jc.2016-3170","volume":"102","author":"Olivier Lamy","year":"2016","unstructured":"Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B. Severe rebound-associated vertebral fractures after denosumab discontinuation: nine clinical cases report. J Clin Endocrinol Metab. 2016:jc20163170. doi: 10.1210\/jc.2016-3170 .","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"1","key":"380_CR70","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12020-016-1030-6","volume":"54","author":"SA Polyzos","year":"2016","unstructured":"Polyzos SA, Terpos E. Clinical vertebral fractures following denosumab discontinuation. Endocrine. 2016;54(1):271\u20132. doi: 10.1007\/s12020-016-1030-6 .","journal-title":"Endocrine"},{"issue":"5","key":"380_CR71","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","volume":"27","author":"AW Popp","year":"2016","unstructured":"Popp AW, Zysset PK, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int: J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found U S A. 2016;27(5):1917\u201321. doi: 10.1007\/s00198-015-3458-6 .","journal-title":"Osteoporos Int: J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found U S A"},{"issue":"4","key":"380_CR72","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1590\/s1679-45082015ao3321","volume":"13","author":"MA Scheinberg","year":"2015","unstructured":"Scheinberg MA, Golmia RP, Sallum AM, Pippa MG, Cortada AP, Silva TG. Bone health in cerebral palsy and introduction of a novel therapy. Einstein (Sao Paulo, Brazil). 2015;13(4):555\u20139. doi: 10.1590\/s1679-45082015ao3321 .","journal-title":"Einstein (Sao Paulo, Brazil)"},{"issue":"7","key":"380_CR73","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s00256-015-2117-5","volume":"44","author":"GR Matcuk Jr","year":"2015","unstructured":"Matcuk GR Jr, Patel DB, Schein AJ, White EA, Menendez LR. Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy. Skelet Radiol. 2015;44(7):1027\u201331. doi: 10.1007\/s00256-015-2117-5 .","journal-title":"Skelet Radiol"},{"issue":"7","key":"380_CR74","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res Off J Am Soc Bone Miner Res. 2012;27(7):1471\u20139. doi: 10.1002\/jbmr.1613 .","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"issue":"1","key":"380_CR75","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00198-011-1755-2","volume":"23","author":"NB Watts","year":"2012","unstructured":"Watts NB, Roux C, Modlin JF, et al. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? Osteoporos Int J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found U S A. 2012;23(1):327\u201337. doi: 10.1007\/s00198-011-1755-2 .","journal-title":"Osteoporos Int J Established Result Coop Eur Found Osteoporos Natl Osteoporos Found U S A"},{"issue":"1","key":"380_CR76","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0092-8674(00)00103-3","volume":"103","author":"JE Fata","year":"2000","unstructured":"Fata JE, Kong YY, Li J, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 2000;103(1):41\u201350.","journal-title":"Cell"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-017-0380-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-017-0380-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-017-0380-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T22:36:46Z","timestamp":1719268606000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-017-0380-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,22]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["380"],"URL":"https:\/\/doi.org\/10.1007\/s11914-017-0380-1","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,22]]},"assertion":[{"value":"22 June 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Alison Boyce declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"This research was supported by the Intramural Research Program of the National Institute of Dental and Craniofacial Research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}